Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | OGA | O60502 | 10/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27022368 | 0.87 | SMN1; SMN2 (0.82) | SMN1; SMN2KMT2AMEN1CYP2D6CYP2C9 | |
| SCHEMBL1722296 | 0.83 | SMN1; SMN2 (0.76) | SMN1; SMN2OGAHTT | |
| SCHEMBL460094 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2OGAHTT | |
| SCHEMBL13128868 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2OGAHTT | |
| SCHEMBL3772589 | 0.78 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL13390908 | 0.76 | KMT2A (0.54) | SMN1; SMN2KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL2666855 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1GAAOGATSHR | |
| SCHEMBL21222206 | 0.75 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1GAATSHR | |
| SCHEMBL27022370 | 0.75 | OGA (0.68) | SMN1; SMN2ALDH1A1OGA | |
| SCHEMBL8834765 | 0.74 | CCNE1 (0.52) | SMN1; SMN2ALDH1A1OGATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | GCK, GCKR, ALDOA | SMN1; SMN2 1746/4885KMT2A 1928/4885MEN1 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.